RTP Mobile Logo
Oncology Today with Dr Neil Love: Myeloproliferative Neoplasms (Video Presentation)
Released November 2021

Featuring perspectives from Dr Ruben Mesa. Published November 1, 2021. (Video Presentation)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myeloproliferative neoplasms.


    • Recall efficacy and safety findings from the JAKARTA and JAKARTA-2 studies evaluating fedratinib for patients with newly diagnosed intermediate-2 or high-risk myelofibrosis and those resistant or intolerant to ruxolitinib, respectively.
    • Appraise the current role of ruxolitinib in the treatment of myelofibrosis, polycythemia vera and essential thrombocythemia, and integrate this agent into clinical treatment algorithms.
    • Evaluate available clinical research data with novel JAK inhibitors (pacritinib, momelotinib) for patients with myelofibrosis, and consider the potential roles of these agents in clinical practice.
    • Assess the tolerability profiles of ruxolitinib and fedratinib, and formulate a side-effect management plan to support quality of life and treatment continuation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Ruben A Mesa, MD
    Executive Director
    Mays Family Foundation Distinguished University Presidential Chair
    UT Health San Antonio MD Anderson Cancer Center
    Mays Cancer Center
    Professor of Medicine
    San Antonio, Texas

    Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Geron, Incyte Corporation, Telios Pharma Inc. Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, CTI BioPharma Corp, Novartis, Sierra Oncology, Telios Pharma Inc. Contracted Research: Blueprint Medicines, Bristol-Myers Squibb Company, CTI BioPharma Corp, Imago BioSciences, Incyte Corporation, Sierra Oncology.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bristol-Myers Squibb Company, CTI BioPharma Corp and Incyte Corporation.

    Release date: November 2021
    Expiration date: November 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):